Atley Solutions
Automated, standardised and reproducible production of At-211 radiopharmaceuticals for targeted alpha therapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
SEK19.7m | Seed | ||
| Total Funding | 000k | ||
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1000 % | 130 % | 1578 % | 118 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1190 %) | (635 %) | (548 %) | (53 %) | (57 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Atley Solutions specializes in the development and commercialization of astatine 211-based radiopharmaceuticals. Founded by two leading astatine radiochemists, the company has pioneered the first automated production module for these radiopharmaceuticals. Atley Solutions offers a comprehensive suite of radiochemical services designed to support clients through every stage of the clinical development journey, from drug discovery to commercialization. The company primarily serves pharmaceutical companies and research institutions focused on cancer treatment. Operating in the niche market of radiopharmaceuticals, Atley Solutions generates revenue through the sale of its automated production modules and radiochemical services. The company's unique value proposition lies in its ability to provide a highly targeted and less toxic local irradiation of cancer cells, facilitated by the favorable half-life of astatine 211.
Keywords: astatine 211, radiopharmaceuticals, cancer treatment, automated production, drug discovery, commercialization, radiochemical services, pharmaceutical companies, research institutions, niche market.